Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Clinical trial NCT06644495 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06644495
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-12-01
- Primary completion
- 2027-04-30
- Enrollment
- 1000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.